NCT05318443View on ClinicalTrials.gov

A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

512

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

December 26, 2022

Study Completion Date

January 12, 2023

Conditions
Non-squamous Non-small-cell Lung Cancer
Interventions
DRUG

SIBP04

SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.

DRUG

Avastin

Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.

DRUG

Paclitaxel

Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.

DRUG

Carboplatin

Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.

Trial Locations (1)

Unknown

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Shanghai Institute Of Biological Products

INDUSTRY

NCT05318443 - A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter